Source comparison
CJC-1295 No DAC vs IGF-1 LR3 — Which Peptide Wins?
Most researchers treating these two peptides as equivalent alternatives are making a fundamental category error. CJC-1295 no DAC (also called modified GRF 1-29) is a growth hormone-releasing hormone (GHRH) analog that stimulates the anterior pituitary to relea
This comparison does not assign a generated winner or score.
- Most researchers treating these two peptides as equivalent alternatives are making a fundamental category error. CJC-1295 no DAC (also called modified GRF 1-29) is a growth hormone-releasing hormone (GHRH) analog that stimulates the anterior pituitary to release endogenous growth hormone in physiological pulses lasting 30 hours post-injection. IGF-1 LR3 (Long R3 IGF-I) is a modified insulin-like growth factor-1 analog with reduced binding affinity to IGF-binding proteins, allowing it to circulate freely for 20–30 hours and act directly on IGF-1 receptors in skeletal muscle, adipose tissue, and connective tissue without requiring growth hormone as an intermediary. The mechanism is upstream versus downstream. And that difference determines everything about dosing, timing, side effect profiles, and research applications.
- Our team at Real Peptides has synthesized both peptides under small-batch, USP-grade protocols for hundreds of research institutions. The confusion we see most often isn't about purity or storage. It's about researchers selecting the wrong peptide for their specific experimental model because they don't understand the biological divergence.
- What's the core difference between CJC-1295 no DAC and IGF-1 LR3?
- CJC-1295 no DAC works by binding to GHRH receptors on somatotroph cells in the anterior pituitary, triggering endogenous growth hormone secretion in pulses that mirror natural circadian patterns. IGF-1 LR3 bypasses the hypothalamic-pituitary-hepatic axis entirely and binds directly to IGF-1 receptors on target tissues, producing anabolic effects independent of growth hormone or hepatic IGF-1 production. The half-life of CJC-1295 no DAC is approximately 30 minutes to 2 hours depending on dosing, while IGF-1 LR3 has a half-life of 20–30 hours due to reduced binding to IGF-binding proteins.
- The real distinction isn't which peptide is 'better'. It's which mechanism your experimental model requires. CJC-1295 no DAC preserves physiological GH pulsatility, making it suitable for models studying neuroendocrine feedback, circadian rhythm interactions, or downstream hepatic IGF-1 production. IGF-1 LR3 delivers direct receptor agonism at target tissues, making it appropriate for localized anabolic studies, muscle protein synthesis models, or research bypassing pituitary function entirely. This article covers the mechanism distinction, dosing protocol differences, experimental application selection criteria, reconstitution and storage requirements for each peptide, and what the peer-reviewed literature actually shows about comparative efficacy in cellular and animal models.